Which practices help mitigate risks when transferring production from clinical to commercial scale?

• A. Process validation, quality by design, early technology transfer, and risk management.
• B. Delaying quality checks until after launch.
• C. Only performing tests on final product, ignoring intermediates.
• D. Relying solely on supplier assurances without validation.

Answer: (A)

Transferring production from clinical to commercial scale hinges on executing a proactive, risk-based approach that keeps quality and regulatory expectations consistent as processes scale up. Process validation confirms that the manufacturing steps provide consistent results under commercial conditions, showing reproducibility and reliability beyond initial runs. Quality by design builds quality into the process from the start by identifying critical parameters and exploring the design space, so adjustments at larger scales stay within controlled boundaries rather than causing unpredictable changes. Early technology transfer captures and transfers essential process knowledge to the commercial site before large-scale production begins, preventing gaps in understanding that could lead to variability or delays. Risk management ties these elements together by systematically identifying potential failures, assessing their impact and likelihood, and implementing mitigations throughout the transfer.

Delaying quality checks until after launch increases the chance of undetected issues and regulatory problems. Testing only final product while ignoring intermediates misses important insights into how the process parameters affect quality. Relying solely on supplier assurances without validation eliminates verification and control, introducing unnecessary risk to quality and supply chain integrity.